Kalypsys Raises $100M

San Diego-based Kalypsys, a firm developing small molecule pharmaceuticals, said today that it has raised $100M in a Series C financing. The funding was led by Tavistock Life Sciences, which contributed $89M to the round. Other investors in the round included Sprout Group, CMEA Ventures, and KT Venture Group. The new round of funding brings the company's total raised to $172M. Kalypsys is developing compounds aimed at metabolic disorders, pain/inflammation, and oncology. More information »